|
Andrew Arnold, M.D.Murray-Heilig Chair in Molecular MedicineProfessor of Medicine and Genetics and Genome Sciences Chief, Division of Endocrinology and Metabolism Director, Center for Molecular Oncology and Chief Academic Officer, Carole and Ray Neag Comprehensive Cancer Center Director, Office of Physician-Scientist Career Development
|
|
Pathogenesis of parathyroid and other endocrine tumors, and role of the cyclin D1 oncogene in neoplasia, including breast cancer.
No data available |
Post-Graduate Training
Training | Institution | Specialty |
---|---|---|
Residency | University of Chicago | Internal Medicine |
Fellowship | Massachusetts General Hospital | Medicine, Endocrinology |
Fellowship | National Cancer Institute/NIH | Molecular Oncology |
Awards
Name of Award/Honor | Awarding Organization |
---|---|
Refer to Abbreviated CV Link |
Parathyroid disorders; genetic/inherited endocrine tumor syndromes
The most longstanding interest of our laboratory has been in the molecular genetic underpinnings of tumors of the endocrine glands. It was in the context of a search for a parathyroid tumor oncogene lying adjacent to a clonal chromosomal breakpoint that we discovered cyclin D1 (PRAD1). Cyclin D1 has proven to play a key role in cell cycle regulation, and has emerged as a major human oncogene, important in multiple types of tumors including breast cancer and B-cell lymphoma. We are currently pursuing a number of approaches, including the use of transgenic mouse models, to learn more about the precise mechanisms by which cyclin D1 exerts its oncogenic effects. In addition to the cyclin D1 work, we are continuing a major initiative seeking additional genes that contribute to endocrine neoplasia. In this context, we identified the HRPT2 gene as a major factor in the development of malignant parathyroid tumors, a finding that carries important clinical implications.
Accepting Lab Rotation Students: Fall 2022 and Spring 2023
Journal Articles
-
Parathyroid Hormone Regulates Circulating Levels of Sclerostin and FGF23 in a Primary Hyperparathyroidism Model.
Journal of the Endocrine Society 2022 Apr;6(4):bvac027
-
GCM2 Variants in Familial and Multiglandular Primary Hyperparathyroidism.
The Journal of Clinical Endocrinology and Metabolism 2021 Dec;
-
Parafibromin Abnormalities in Ossifying Fibroma.
Journal of the Endocrine Society 2021 Jul;5(7):bvab087
-
Hormonal regulation of biomineralization.
Nature reviews. Endocrinology 2021 May;17(5):261-275
-
Molecular analysis of cyclin D1 modulators PRKN and FBX4 as candidate tumor suppressors in sporadic parathyroid adenomas.
Endocrine connections 2021 Mar;10(3):302-308
-
CDK4/6 Dependence of Cyclin D1-Driven Parathyroid Neoplasia in Transgenic Mice.
Endocrinology 2020 Oct;161(10):